Magstim’s Post

New TMS research: Effects of 52 weeks of precuneus rTMS in Alzheimer’s disease patients: a randomized trial Article states, "Personalized repetitive transcranial magnetic stimulation (rTMS) of the precuneus (PC) is emerging as a new non-invasive therapeutic approach in treating Alzheimer’s disease (AD). Here we sought to investigate the effects of 52 weeks of rTMS applied over the PC on cognitive functions in patients with mild-to-moderate dementia due to AD.." Results: "Among 48 patients randomized (mean age 72.8 years; 56% women), 32 (68%) completed the study. Repetitive TMS of the PC (PC-rTMS) had a significant effect on the primary outcome measure. The estimated mean change in CDR-SB after 52 week was 1.36 for PC-rTMS (95% confidence interval (CI) [0.68, 2.04]) and 2.45 for sham-rTMS group (95%CI [1.85, 3.05]). There were also significant effects for the secondary outcomes ADAS-Cog11, ADCS-ADL and NPI scores. Stronger DMN connectivity at baseline was associated with favorable response to rTMS treatment." rTMS was carried out using a Magstim Rapid2 magnetic biphasic stimulator connected with a 70-mm diameter figure-of-eight coil (Magstim Company, Whitland, UK). #TMS #alzheimers #brain #neurotech Read the article here: https://lnkd.in/gFhDNh49